Nomacopan, formerly known as rVA576 (Coversin), a second-generation C5 complement inhibitor, is a bi-functional recombinant small protein which is currently in phase 3 of clinical development for PNH (NCT03588026). Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.